Jos J Lucas

List of Publications by Year in Descending Order

112 papers	8,672 citations	48 h-index	92 g-index
117 ext. papers	9,559 ext. citations	8.5 avg, IF	5.7 L-index

#	Paper	IF	Citations
112	Huntington's disease-specific mis-splicing unveils key effector genes and altered splicing factors. *Brain*, **2021**, 144, 2009-2023	11.2	4
111	Huntingtin-mediated axonal transport requires arginine methylation by PRMT6. *Cell Reports*, **2021**, 35, 108980	10.6	3
110	A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease. *Acta Neuropathologica*, **2021**, 142, 159-177	14.3	3
109	CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease. *Science Translational Medicine*, **2021**, 13, eabe7104	17.5	0
108	Prion-Associated Neurodegeneration Causes Both Endoplasmic Reticulum Stress and Proteasome Impairment in a Murine Model of Spontaneous Disease. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
107	P2X7 Receptor Upregulation in Huntington's Disease Brains. *Frontiers in Molecular Neuroscience*, **2020**, 13, 567430	6.1	8
106	Pathogenic SREK1 decrease in Huntington's disease lowers TAF1 mimicking X-linked dystonia parkinsonism. *Brain*, **2020**, 143, 2207-2219	11.2	9
105	Polyadenylation of mRNA as a novel regulatory mechanism of gene expression in temporal lobe epilepsy. *Brain*, **2020**, 143, 2139-2153	11.2	2
104	High concordance between hippocampal transcriptome of the mouse intra-amygdala kainic acid model and human temporal lobe epilepsy. *Epilepsia*, **2020**, 61, 2795-2810	6.4	7
103	Differential regulation of Kidins220 isoforms in Huntington's disease. *Brain Pathology*, **2020**, 30, 120-136	6	1
102	Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome. *Neurobiology of Disease*, **2019**, 127, 210-222	7.5	14
101	Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease. *Frontiers in Cellular Neuroscience*, **2019**, 13, 574	6.1	14
100	Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing. *Nature*, **2018**, 560, 441-446	50.4	62
99	Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17. *International Journal of Physiology, Pathophysiology and Pharmacology*, **2018**, 10, 172-183	3.4	2
98	The regulation of proteostasis in glial cells by nucleotide receptors is key in acute neuroinflammation. *FASEB Journal*, **2018**, 32, 3020-3032	0.9	6
97	Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus. *Cell Death and Disease*, **2018**, 9, 969	9.8	16
96	MAP2 Splicing is Altered in Huntington's Disease. *Brain Pathology*, **2017**, 27, 181-189	6	15

95	Tau-positive nuclear indentations in P301S tauopathy mice. *Brain Pathology*, **2017**, 27, 314-322	6	9
94	Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury. *Molecular Neurodegeneration*, **2017**, 12, 21	19	11
93	The neuroprotective transcription factor ATF5 is decreased and sequestered into polyglutamine inclusions in Huntington's disease. *Acta Neuropathologica*, **2017**, 134, 839-850	14.3	7
92	Regulation of proteasome activity by P2Y receptor underlies the neuroprotective effects of extracellular nucleotides. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2017**, 1863, 43-51	6.9	4
91	Faulty splicing and cytoskeleton abnormalities in Huntington's disease. *Brain Pathology*, **2016**, 26, 772-778	6	21
90	Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system. *Acta Neuropathologica*, **2016**, 131, 411-25	14.3	44
89	Impaired PLP-dependent metabolism in brain samples from Huntington disease patients and transgenic R6/1 mice. *Metabolic Brain Disease*, **2016**, 31, 579-86	3.9	3
88	Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome. *Brain Pathology*, **2016**, 26, 593-605	6	96
87	Mice Lacking Functional Fas Death Receptors Are Protected from Kainic Acid-Induced Apoptosis in the Hippocampus. *Molecular Neurobiology*, **2015**, 52, 120-9	6.2	5
86	Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease. *Human Molecular Genetics*, **2015**, 24, 5040-52	5.6	27
85	In vivo inhibition of the mitochondrial H+-ATP synthase in neurons promotes metabolic preconditioning. *EMBO Journal*, **2014**, 33, 762-78	13	64
84	Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice. *European Neuropsychopharmacology*, **2014**, 24, 1524-33	1.2	9
83	Huntington's disease is a four-repeat tauopathy with tau nuclear rods. *Nature Medicine*, **2014**, 20, 881-5	50.5	135
82	Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice. *Human Molecular Genetics*, **2014**, 23, 767-81	5.6	14
81	Ubiquitin-proteasome system involvement in Huntington's disease. *Frontiers in Molecular Neuroscience*, **2014**, 7, 77	6.1	67
80	Mice with a naturally occurring DISC1 mutation display a broad spectrum of behaviors associated to psychiatric disorders. *Frontiers in Behavioral Neuroscience*, **2014**, 8, 253	3.5	22
79	Mutant huntingtin affects endocytosis in striatal cells by altering the binding of AP-2 to membranes. *Experimental Neurology*, **2013**, 241, 75-83	5.7	13
78	GSK3 and tau: two convergence points in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2013**, 33 Suppl 1, S141-4	4.3	162

77	CHOP regulates the p53-MDM2 axis and is required for neuronal survival after seizures. *Brain*, **2013**, 136, 577-92	11.2	74
76	Protective neuronal induction of ATF5 in endoplasmic reticulum stress induced by status epilepticus. *Brain*, **2013**, 136, 1161-76	11.2	33
75	Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent. *PLoS ONE*, **2013**, 8, e70952	3.7	5
74	Age-dependent decline of motor neocortex but not hippocampal performance in heterozygous BDNF mice correlates with a decrease of cortical PSD-95 but an increase of hippocampal TrkB levels. *Experimental Neurology*, **2012**, 237, 335-45	5.7	21
73	Synuclein levels affect autophagosome numbers in vivo and modulate Huntington disease pathology. *Autophagy*, **2012**, 8, 431-2	10.2	17
72	Looking for novel functions of tau. *Biochemical Society Transactions*, **2012**, 40, 653-5	5.1	15
71	Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease. *Human Molecular Genetics*, **2012**, 21, 495-510	5.6	25
70	Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. *Journal of Neuroscience*, **2011**, 31, 8150-62	6.6	55
69	GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. *Frontiers in Molecular Neuroscience*, **2011**, 4, 45	6.1	49
68	Impaired ATF6 processing, decreased Rheb and neuronal cell cycle re-entry in Huntington's disease. *Neurobiology of Disease*, **2011**, 41, 23-32	7.5	35
67	Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. *Brain*, **2011**, 134, 119-36	11.2	154
66	Increased neurotransmitter release at the neuromuscular junction in a mouse model of polyglutamine disease. *Journal of Neuroscience*, **2011**, 31, 1106-13	6.6	34
65	GSK3 overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. *Hippocampus*, **2011**, 21, 910-22	3.5	61
64	PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. *Cell Death and Differentiation*, **2010**, 17, 324-35	12.7	42
63	Centro de Biologia Molecular "Severo Ochoa": a center for basic research into Alzheimer's disease. *Journal of Alzheimers Disease*, **2010**, 21, 325-35	4.3	
62	Tau kinase I overexpression induces dentate gyrus degeneration. *Neurodegenerative Diseases*, **2010**, 7, 13-5	2.3	4
61	Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. *Journal of Neuroscience*, **2010**, 30, 3675-88	6.6	76
60	GSK3: a possible link between beta amyloid peptide and tau protein. *Experimental Neurology*, **2010**, 223, 322-5	5.7	200

59	Presynaptic dysfunction in Huntington's disease. *Biochemical Society Transactions*, **2010**, 38, 488-92	5.1	26
58	Tau phosphorylation in hippocampus results in toxic gain-of-function. *Biochemical Society Transactions*, **2010**, 38, 977-80	5.1	21
57	Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. *Neurobiology of Disease*, **2010**, 37, 622-9	7.5	87
56	Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. *Free Radical Biology and Medicine*, **2010**, 49, 612-21	7.8	66
55	NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. *Journal of Clinical Investigation*, **2010**, 120, 2432-45	15.9	64
54	Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 13986-91	11.5	72
53	Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. *FASEB Journal*, **2009**, 23, 1893-906	0.9	180
52	Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity. *Neurobiology of Disease*, **2009**, 36, 461-9	7.5	32
51	Effects of partial suppression of parkin on huntingtin mutant R6/1 mice. *Brain Research*, **2009**, 1281, 91-100	3.7	21
50	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. *European Journal of Neurology*, **2009**, 16, 297-309	6	143
49	The role of GSK3 in Alzheimer disease. *Brain Research Bulletin*, **2009**, 80, 248-50	3.9	59
48	Hippocampal neuronal subpopulations are differentially affected in double transgenic mice overexpressing frontotemporal dementia and parkinsonism linked to chromosome 17 tau and glycogen synthase kinase-3beta. *Neuroscience*, **2008**, 157, 772-80	3.9	8
47	Lithium, a potential protective drug in Alzheimer's disease. *Neurodegenerative Diseases*, **2008**, 5, 247-9	2.3	37
46	Co-expression of FTDP-17 Human Tau and GSK-3β (or APPSW) in Transgenic Mice: Induction of Tau Polymerization and Neurodegeneration **2008**, 337-342		
45	A mouse model to study tau pathology related with tau phosphorylation and assembly. *Journal of the Neurological Sciences*, **2007**, 257, 250-4	3.2	7
44	BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. *Journal of Neuroscience Research*, **2007**, 85, 2756-69	4.4	29
43	Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. *EMBO Journal*, **2007**, 26, 2743-54	13	54
42	Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. *European Journal of Neuroscience*, **2007**, 25, 81-6	3.5	268

41	Is the ubiquitin-proteasome system impaired in Huntington's disease?. *Cellular and Molecular Life Sciences*, **2007**, 64, 2245-57	10.3	54
40	N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. *Journal of Biological Chemistry*, **2007**, 282, 22406-13	5.4	99
39	Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin. *Brain Research Bulletin*, **2007**, 72, 121-3	3.9	6
38	Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. *Journal of Neuroscience*, **2006**, 26, 5083-90	6.6	217
37	Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. *Neurobiology of Aging*, **2006**, 27, 1258-68	5.6	96
36	Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. *European Journal of Neuroscience*, **2006**, 23, 649-58	3.5	107
35	Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. *Journal of Neurochemistry*, **2006**, 98, 1585-96	6	77
34	Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. *Journal of Neurochemistry*, **2006**, 99, 1445-55	6	169
33	The Ups in Neurodegenerative Diseases and Aging Huntington Disease **2006**, 225-235		
32	The ubiquitin-proteasome system in Huntington's disease. *Neuroscientist*, **2005**, 11, 583-94	7.6	42
31	Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. *Journal of Neuroscience*, **2005**, 25, 9773-81	6.6	61
30	Assembly in vitro of tau protein and its implications in Alzheimer's disease. *Current Alzheimer Research*, **2004**, 1, 97-101	3	21
29	Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. *Journal of Neuroscience*, **2004**, 24, 9361-71	6.6	47
28	Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. *Journal of Biological Chemistry*, **2004**, 279, 3801-6	5.4	103
27	Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. *Neurotoxicity Research*, **2004**, 6, 463-8	4.3	36
26	Tau in neurodegenerative diseases: tau phosphorylation and assembly. *Neurotoxicity Research*, **2004**, 6, 477-82	4.3	39
25	Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo. *Trends in Neurosciences*, **2004**, 27, 66-9	13.3	33
24	Role of tau protein in both physiological and pathological conditions. *Physiological Reviews*, **2004**, 84, 361-84	47.9	641

23	Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. *Journal of Neuropathology and Experimental Neurology*, **2004**, 63, 484-98	3.1	69
22	Neuronal induction of the immunoproteasome in Huntington's disease. *Journal of Neuroscience*, **2003**, 23, 11653-61	6.6	218
21	GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. *Neurobiology of Aging*, **2003**, 24, 1087-94	5.6	36
20	Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. *Journal of Biological Chemistry*, **2003**, 278, 45937-45	5.4	393
19	Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. *Brain Research*, **2002**, 929, 236-42	3.7	93
18	Sulfo-glycosaminoglycan content affects PHF-tau solubility and allows the identification of different types of PHFs. *Brain Research*, **2002**, 935, 65-72	3.7	17
17	Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. *Journal of Neurochemistry*, **2002**, 83, 1529-33	6	291
16	Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. *European Journal of Neuroscience*, **2002**, 16, 355-9	3.5	19
15	Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. *EMBO Journal*, **2001**, 20, 27-39	13	670
14	FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. *Molecular and Cellular Neurosciences*, **2001**, 18, 702-14	4.8	176
13	Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. *Journal of Neuroscience*, **2001**, 21, 8772-81	6.6	136
12	Modulation of the effects of cocaine by 5-HT1B receptors: a comparison of knockouts and antagonists. *Pharmacology Biochemistry and Behavior*, **2000**, 67, 559-66	3.9	81
11	Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. *Cell*, **2000**, 101, 57-66	56.2	899
10	Nuclear localization of beta-catenin in adult mouse thalamus correlates with low levels of GSK-3beta. *NeuroReport*, **1999**, 10, 2699-703	1.7	12
9	Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. *Nature*, **1998**, 393, 175-8	50.4	276
8	Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. *Journal of Neuroscience*, **1998**, 18, 5537-44	6.6	136
7	5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. *Molecular Pharmacology*, **1997**, 51, 755-63	4.3	81
6	Peripheral noxious stimulation induces CREM expression in dorsal horn: involvement of glutamate. *European Journal of Neuroscience*, **1997**, 9, 2778-83	3.5	12

5	New players in the 5-HT receptor field: genes and knockouts. *Trends in Pharmacological Sciences*, **1995**, 16, 246-52	13.2	102
4	Molecular mechanisms of pain: serotonin1A receptor agonists trigger transactivation by c-fos of the prodynorphin gene in spinal cord neurons. *Neuron*, **1993**, 10, 599-611	13.9	90
3	Co-induction of jun B and c-fos in a subset of neurons in the spinal cord. *Oncogene*, **1991**, 6, 223-7	9.2	54
2	Animal Models with Modified Expression of GSK-3 for the Study of Its Physiology and of Its Implications in Human Pathologies203-219		
1	Huntington disease-specific mis-splicing captured by human-mouse intersect-RNA-seq unveils pathogenic effectors and reduced splicing factors		4